A Bayesian three-tier quantitative decision-making framework for single arm studies in early phase oncology

References

• Cartwright, M., S. Cohen, J. Fleishaker, S. Madani, J. McLeod, B. Musser, and S. Williams. 2010. Proof of concept: A phrma position paper with recommendations for best practice. Clinical Pharmacology and Therapeutics 87(3):278–285. doi:10.1038/clpt.2009.286.
   PubMed Web of Science ®Google Scholar
• Chen, C., L. Sun, and C.-L. Li. 2013. Evaluation of early efficacy endpoints for proof-of-concept trials. Journal of Biopharmaceutical Statistics 23(2):413–424. doi:10.1080/10543406.2011.616969.
   PubMed Web of Science ®Google Scholar
• Fisch, R., I. Jones, J. Jones, J. Kerman, G. K. Rosenkranz, and H. Schmidli. 2015. Bayesian design of proof-of-concept trials. Therapeutic Innovation & Regulatory Science 49(1):155–162. doi:10.1177/2168479014533970.
   PubMed Web of Science ®Google Scholar
• Frewer, P., P. Mitchell, C. Watkins, and J. Matcham. 2016. Decision-making in early clinical drug development. Pharmaceutical Statistics 15(3):255–263. doi:10.1002/pst.1746.
   PubMed Web of Science ®Google Scholar
• Jemielita, T., A. Tse, and C. Chen. 2019. Oncology phase ii proof-of-concept studies with multiple targets: Randomized controlled trial or single arm? Pharmaceutical Statistics 19(2):117–125. doi:10.1002/pst.1972.
   PubMed Web of Science ®Google Scholar
• Lalonde, R., K. Kowalski, M. Hutmacher, W. Ewy, D. Nichols, P. Milligan, B. Corrigan, P. Lockwood, S. Marshall, L. Benincosa, et al. 2007. Model-based drug development. Clinical Pharmacology and Therapeutics 82(1):21–32. doi:10.1038/sj.clpt.6100235.
   PubMed Web of Science ®Google Scholar
• Langer, C., S. Gadgeel, H. Borghaei, V. Papadimitrakopoulou, A. Patnaik, S. F. Powell, R. D. Gentzler, R. G. Martins, J. P. Stevenson, and S. I. Jalal. 2016. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label keynote-021 study. The Lancet Oncology 17(11):1497–1508. doi:10.1016/S1470-2045(16)30498-3.
   PubMed Web of Science ®Google Scholar
• Long, G. V., R. Dummer, O. Hamid, T. F. Gajewski, C. Caglevic, S. Dalle, A. Arance, M. S. Carlino, -J.-J. Grob, T. M. Kim, et al. 2019. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (echo-301/keynote-252): A phase 3, randomised, double-blind study. The Lancet Oncology 20(8):1083–1097. doi:10.1016/S1470-2045(19)30274-8.
   PubMed Web of Science ®Google Scholar
• Pulkstenis, E., K. Patra, and J. Zhang. 2017. A Bayesian paradigm for decision-making in proof-of-concept trials. Journal of Biopharmaceutical Statistics 27(3):442–456. doi:10.1080/10543406.2017.1289947.
   PubMed Web of Science ®Google Scholar
• Sargent, D., V. Chan, and R. Goldberg. 2001. A three-outcome design for phase ii clinical trials. Controlled Clinical Trials 22(2):117–125. doi:10.1016/S0197-2456(00)00115-X.
   PubMedGoogle Scholar
• Simon, R. 1989. Optimal two-stage designs for phase ii clinical trials. Controlled Clinical Trials 10(1):1–10. doi:10.1016/0197-2456(89)90015-9.
   PubMedGoogle Scholar
• Thall, P., and R. Simon. 1990. Incorporating historical control data in planning phase ii clinical trials. Statistics in Medicine 9(3):215–228. doi:10.1002/sim.4780090304.
   PubMed Web of Science ®Google Scholar
• Thall, P., and R. Simon. 1994. Practical Bayesian guidelines for phase iib clinical trials. Biometrics 50(2):337–349. doi:10.2307/2533377.
   PubMed Web of Science ®Google Scholar
• Thall, P., R. Simon, and E. Estey. 1995. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Statistics in Medicine 14(4):357–379. doi:10.1002/sim.4780140404.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. 2018. Expansion cohorts: Use in first-in-human clinical trials to expedite development of oncology drugs and biologics guidance for industry.
   Google Scholar
• Walley, R., C. Smith, J. Gale, and P. Woodward. 2015. Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: A case study. Pharmaceutical Statistics 14(3):205–215. doi:10.1002/pst.1675.
   PubMed Web of Science ®Google Scholar
• Wang, Y., H. Fu, P. Kulkarni, and C. Kaiser. 2013. Evaluating and utilizing probability of study success in clinical development. Clinical Trials 10(3):407–413. doi:10.1177/1740774513478229.
   PubMed Web of Science ®Google Scholar
• Xin, Y., V. Hubbard-Lucey, and J. Tang. 2019. Immuno-oncology drug development goes global. Nature Reviews. Drug Discovery 18(12):899. doi:10.1038/d41573-019-00167-9.
   PubMed Web of Science ®Google Scholar
• Zhou, H., J. Lee, and Y. Yuan. 2017. Bop2: Bayesian optimal design for phase ii clinical trials with simple and complex endpoints. Statistics in Medicine 36(21):3302–3314. doi:10.1002/sim.7338.
   PubMed Web of Science ®Google Scholar